Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label etelcalcetide study in pediatric secondary hyperparathyroidism on hemodialysis
2023-506471-10-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Jan 2024
- Modality
- Small Molecules, Peptides
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of etelcalcetide in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), sponsored by Amgen. Primary endpoint: Percent change in iPTH from baseline during the efficacy assessment period. Planned start Jan 2024; status: authorised.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-506471-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506471-10-00.